Uncategorized

Analysts predict the contract could be worth up to $54 million for Amwell alone over its 22-month term.

Nanavaty has taken up the post after spending 18 years at Boston Scientific, where he held senior roles in interventional cardiology and neuromodulation.

Some doctors think TAVR may perform numerically worse but see little impact on the market unless there is a statistically significant result.

Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company.

The Board of Directors of Bioretec Ltd has on 20 October 2023 decided, on the basis of the authorization received from the company’s Annual General Meeting on 26 May 2023, to establish a new option program as an incentive scheme for the employees and consultants and members of the company’s Key Opinion Leader group of

Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography scans to assess the status amyloid plaque in the brain.

Gilead Sciences, Inc. presented new data supporting Sunlenca® as an important treatment option for adults with multi-drug resistant HIV who have extensive treatment history.

Internet, la red global que ha revolucionado la forma en que vivimos, trabajamos y nos comunicamos, está en constante evolución. A medida que avanzamos en el siglo XXI, nos encontramos en un emocionante punto de inflexión que promete transformar aún más la red que …

Alaya.bio, an in vivo gene delivery biotech company, announces the acquisition of all assets previously owned by Ixaka France, a preclinical-stage immunotherapy biotech company specializing in in vivo CAR T-cell therapy.

GC Genome Corporation, a leading diagnostics company, announced that it will present data showcasing deep learning algorithm utilizing methylation markers that can identify lung cancer at the European Society for Medical Oncology 2023 Congress, taking place from October 20-24 in Madrid, Spain.